Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors
- PMID: 26927331
- DOI: 10.1016/j.jmoldx.2015.11.009
Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors
Abstract
The methylation status of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene is an important predictive biomarker for benefit from alkylating agent therapy in glioblastoma. Our model MGMT-STP27 allows prediction of the methylation status of the MGMT promoter using data from the Illumina's Human Methylation BeadChips (HM-27K and HM-450K) that is publically available for many cancer data sets. Here, we investigate the impact of the context of genetic and epigenetic alterations and tumor type on the classification and report on technical aspects, such as robustness of cutoff definition and preprocessing of the data. The association between gene copy number variation, predicted MGMT methylation, and MGMT expression revealed a gene dosage effect on MGMT expression in lower grade glioma (World Health Organization grade II/III) that in contrast to glioblastoma usually carry two copies of chromosome 10 on which MGMT resides (10q26.3). This implies some MGMT expression, potentially conferring residual repair function blunting the therapeutic effect of alkylating agents. A sensitivity analyses corroborated the performance of the original cutoff for various optimization criteria and for most data preprocessing methods. Finally, we propose an R package mgmtstp27 that allows prediction of the methylation status of the MGMT promoter and calculation of appropriate confidence and/or prediction intervals. Overall, MGMT-STP27 is a robust model for MGMT classification that is independent of tumor type and is adapted for single sample prediction.
Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.Acta Neuropathol. 2012 Oct;124(4):547-60. doi: 10.1007/s00401-012-1016-2. Epub 2012 Jul 19. Acta Neuropathol. 2012. PMID: 22810491 Free PMC article.
-
Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.J Neurooncol. 2015 May;122(3):441-50. doi: 10.1007/s11060-015-1738-9. Epub 2015 Feb 15. J Neurooncol. 2015. PMID: 25682093
-
MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.Clin Epigenetics. 2016 May 5;8:49. doi: 10.1186/s13148-016-0204-7. eCollection 2016. Clin Epigenetics. 2016. PMID: 27158275 Free PMC article.
-
MGMT testing--the challenges for biomarker-based glioma treatment.Nat Rev Neurol. 2014 Jul;10(7):372-85. doi: 10.1038/nrneurol.2014.100. Epub 2014 Jun 10. Nat Rev Neurol. 2014. PMID: 24912512 Review.
-
The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.World J Surg Oncol. 2016 Oct 12;14(1):261. doi: 10.1186/s12957-016-1012-4. World J Surg Oncol. 2016. PMID: 27733166 Free PMC article. Review.
Cited by
-
Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review.Front Oncol. 2024 Jul 26;14:1405267. doi: 10.3389/fonc.2024.1405267. eCollection 2024. Front Oncol. 2024. PMID: 39132504 Free PMC article.
-
No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients.Neuro Oncol. 2024 Oct 3;26(10):1867-1875. doi: 10.1093/neuonc/noae108. Neuro Oncol. 2024. PMID: 38912869 Free PMC article.
-
A prognostic neural epigenetic signature in high-grade glioma.Nat Med. 2024 Jun;30(6):1622-1635. doi: 10.1038/s41591-024-02969-w. Epub 2024 May 17. Nat Med. 2024. PMID: 38760585 Free PMC article.
-
Glioma.Nat Rev Dis Primers. 2024 May 9;10(1):33. doi: 10.1038/s41572-024-00516-y. Nat Rev Dis Primers. 2024. PMID: 38724526 Review.
-
Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?J Neuropathol Exp Neurol. 2024 Apr 19;83(5):357-364. doi: 10.1093/jnen/nlae018. J Neuropathol Exp Neurol. 2024. PMID: 38447592 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials